BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33721342)

  • 1. Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis.
    Gragnani L; Lorini S; Marri S; Basile U; Santarlasci V; Monti M; Madia F; Petraccia L; Stasi C; Marello N; Napodano C; Annunziato F; Zignego AL
    Hepatology; 2021 Sep; 74(3):1164-1173. PubMed ID: 33721342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure.
    Bonacci M; Lens S; Mariño Z; Londoño MC; Rodriguez-Tajes S; Sánchez-Tapias JM; Ramos-Casals M; Hernández-Rodríguez J; Forns X
    Gastroenterology; 2018 Aug; 155(2):311-315.e6. PubMed ID: 29705529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 28B gene polymorphisms in hepatitis C virus-related cryoglobulinemic vasculitis.
    Sansonno D; Russi S; Serviddio G; Conteduca V; D'Andrea G; Sansonno L; Pavone F; Lauletta G; Mariggiò MA; Dammacco F
    J Rheumatol; 2014 Jan; 41(1):91-8. PubMed ID: 24293567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience.
    Passerini M; Schiavini M; Magni CF; Landonio S; Niero F; Passerini S; Croci AL; Bolis M; Scalzi V; Gubertini G; Ricci ED; Galli M; Rizzardini G
    Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1208-1215. PubMed ID: 30138160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis.
    Dammacco F; Lauletta G; Russi S; Leone P; Tucci M; Manno C; Monaco S; Ferrari S; Vacca A; Racanelli V
    Clin Exp Med; 2019 Feb; 19(1):1-21. PubMed ID: 30430284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals.
    Bonacci M; Lens S; Londoño MC; Mariño Z; Cid MC; Ramos-Casals M; Sánchez-Tapias JM; Forns X; Hernández-Rodríguez J
    Clin Gastroenterol Hepatol; 2017 Apr; 15(4):575-583.e1. PubMed ID: 27725289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of Cryoglobulinemia in Direct-Acting Antiviral-Treated Asian Hepatitis C Patients With Sustained Virological Responses: A 4-Year Prospective Cohort Study.
    Chang ML; Cheng JS; Chuang YH; Pao LH; Wu TS; Chen SC; Chang MY; Chien RN
    Front Immunol; 2022; 13():823160. PubMed ID: 35371039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
    Comarmond C; Garrido M; Pol S; Desbois AC; Costopoulos M; Le Garff-Tavernier M; Si Ahmed SN; Alric L; Fontaine H; Bellier B; Maciejewski A; Rosenzwajg M; Klatzmann D; Musset L; Poynard T; Cacoub P; Saadoun D
    Gastroenterology; 2017 Jun; 152(8):2052-2062.e2. PubMed ID: 28274850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis.
    Gragnani L; Lorini S; Martini L; Stasi C; Visentini M; Petraccia L; Marello N; Monti M; Marri S; Madia F; Ricca V; Zignego AL
    Clin Rheumatol; 2022 Jan; 41(1):147-157. PubMed ID: 34409558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort.
    Kondili LA; Monti M; Quaranta MG; Gragnani L; Panetta V; Brancaccio G; Mazzaro C; Persico M; Masarone M; Gentile I; Andreone P; Madonia S; Biliotti E; Filomia R; Puoti M; Fracanzani AL; Laccabue D; Ieluzzi D; Coppola C; Rumi MG; Benedetti A; Verucchi G; Coco B; Chemello L; Iannone A; Ciancio A; Russo FP; Barbaro F; Morisco F; Chessa L; Massari M; Blanc P; Zignego AL
    Hepatology; 2022 Jul; 76(1):220-232. PubMed ID: 34919289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life.
    Gragnani L; Lorini S; Marri S; Vacchi C; Madia F; Monti M; Ferri C; Zignego AL
    Autoimmun Rev; 2022 Jan; 21(1):102923. PubMed ID: 34419670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.
    Emery JS; Kuczynski M; La D; Almarzooqi S; Kowgier M; Shah H; Wong D; Janssen HLA; Feld JJ
    Am J Gastroenterol; 2017 Aug; 112(8):1298-1308. PubMed ID: 28291241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T(14;18) is not associated with mixed cryoglobulinemia or with clonal B cell expansion in egyptian patients with hepatitis C virus infection.
    Abbas OM; Omar NA; Hassan ZK
    J Egypt Natl Canc Inst; 2008 Jun; 20(2):149-57. PubMed ID: 20029471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse of Hepatitis C Virus Cryoglobulinemic Vasculitis After Sustained Viral Response After Interferon-Free Direct-Acting Antivirals.
    Fayed A; Hegazy MT; Biard L; Vieira M; El Shabony T; Saadoun D; Casato M; Visentini M; Ragab G; Cacoub P
    Am J Gastroenterol; 2022 Apr; 117(4):627-636. PubMed ID: 35103020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements.
    Dammacco F; Lauletta G; Vacca A
    Clin Exp Med; 2023 Jun; 23(2):255-272. PubMed ID: 35348938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis.
    Saadoun D; Pol S; Ferfar Y; Alric L; Hezode C; Si Ahmed SN; de Saint Martin L; Comarmond C; Bouyer AS; Musset L; Poynard T; Resche Rigon M; Cacoub P
    Gastroenterology; 2017 Jul; 153(1):49-52.e5. PubMed ID: 28288791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis.
    Gragnani L; Cerretelli G; Lorini S; Steidl C; Giovannelli A; Monti M; Petraccia L; Sadalla S; Urraro T; Caini P; Xheka A; Simone A; Arena U; Matucci-Cerinic M; Vergani D; Laffi G; Zignego AL
    Aliment Pharmacol Ther; 2018 Aug; 48(4):440-450. PubMed ID: 29952013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of immunoglobulin free light chains in patients with chronic hepatitis C presenting cryoglobulinemia.
    Oliveira IS; Cabral MS; Jesus LS; Paraná R; Atta AM; Sousa Atta ML
    Braz J Infect Dis; 2014; 18(6):638-42. PubMed ID: 25193081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between IFN-λ 3 Gene Polymorphisms and Outcome of Treatment with Direct Acting Antivirals in Chronic HCV-Infected Egyptian Patients.
    El-Garawani I; Hassab El-Nabi S; Gadallah M; Abdelsameea E
    Immunol Invest; 2021 Jan; 50(1):12-22. PubMed ID: 32024403
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis.
    Cacoub P; Si Ahmed SN; Ferfar Y; Pol S; Thabut D; Hezode C; Alric L; Comarmond C; Ragab G; Quartuccio L; Hegazy M; Poynard T; Resche Rigon M; Saadoun D
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):518-526. PubMed ID: 29857143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.